Healthcare & Life Sciences
Trivitron raised private equity from India Value Fund
About
Trivitron
Trivitron is a global MedTech company of Indian origin focused on manufacturing, innovation, distribution and best-in-class after sales support, thus matching all the healthcare requirements across the globe. Trivitron, through its innovations and collaborative initiatives, makes healthcare accessible and affordable to the developed and emerging markets.
Trivitron’s key focus segments include Imaging Sciences, Diagnostics (IVD), Critical Life Support Solutions (CLSS), Cardiology & Implantable Devices, and Ophthalmology, boasting as one of the most comprehensive solution offerings in value and premium segments in the Medical Technology space across the globe, backed up by best-in-class after sales support.
Trivitron built a strong pan-India distribution channel catering to different regions as well as to other emerging markets. It also has a credible track record of creating strong franchisees in India/SE Asia for global medical equipment majors including Hitachi, Hologic, Thermo Fisher, Sebia & Diasorin.
India Value Fund Advisors
India Value Fund Advisors (“IVFA”) was established in 2000 and is one of the most experienced private equity fund managers in India. IVFA manages over US$1.3 billion in assets across four funds of India Value Fund.
IVFA’s investment strategy is to acquire majority / significant minority stakes in mid-size companies in India to build high growth and enduring businesses, which are admired by all stakeholders. An in-house business management team, with deep operating experience, supports IVFA’s unique value creation approach of partnering with portfolio companies to transform businesses. IVFA’s investments include a diverse range of industries such as healthcare, retailing, outsourced services, consumer products and services, media & entertainment and manufacturing. Healthcare is a focus area for IVFA with several investments like Biocon, Care Hospitals, TTK Healthcare Services and DM Healthcare.
Background
We are pleased to announce that our client Trivitron Healthcare Private Limited (“Trivitron”) has received an investment of Rs 150 crores from India Value Fund. The transaction is a combination of IVF’s primary investment into Trivitron Healthcare for funding its growth and expansion plans and secondary purchase of the remaining stakes of ePlanet Ventures Mauritius Limited (“ePlanet”) & HAV2 (Mauritius) Limited (“Headland”) in the Company. Fidelity Capital Management (Mauritius) Limited and its affiliates, which had invested in the Company last year, continue to hold their stake in Trivitron.
Veda Corporate Advisors (“VedaCorp”) was the exclusive advisor to Trivitron & exiting shareholders in the transaction. This is VedaCorp’s third Private Equity transaction for Trivitron Group and reflects its deep relationship with the Promoter Group led by Dr G.S.K.Velu. This transaction envisaged complex structuring to meet the requirements of the Promoters, the existing investor, exiting investors and the incoming investor. VedaCorp provided comprehensive transaction advisory services covering strategic positioning, valuation and transaction structuring and support in negotiation and finalization of definitive agreements, leading to the successful closure of the transaction.
VedaCorp was also the exclusive advisor to Trivitron when ePlanet and Headland invested in 2007. This is the sixth company that VedaCorp has advised both at the time of entry and successful exit of a private equity investor – Testimony to VedaCorp’s focus on long-term partnership and ability to deliver value to all shareholders over an investment life cycle.